Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.57 |
| ▸ | BRD4 | O60885 | 4/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 11/20 | 0.51 |
| ▸ | MAOA | P21397 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15052427 | 0.90 | PARP1 (0.61) | CREBBPBRD4PARP1MAOBMAOA | |
| SCHEMBL15080158 | 0.90 | PARP1 (0.61) | CREBBPBRD4PARP1MAOBMAOA | |
| SCHEMBL6295593 | 0.85 | BRD4 (0.50) | CREBBPBRD4PARP1MAOBMAOA | |
| SCHEMBL18823877 | 0.85 | CREBBP (0.52) | CREBBPBRD4MAOBMAOANPC1 | |
| SCHEMBL19518160 | 0.82 | CREBBP (0.80) | CREBBPBRD4MAOBMAOA | |
| SCHEMBL17673304 | 0.82 | CREBBP (0.80) | CREBBPBRD4MAOBMAOA | |
| SCHEMBL9195493 | 0.82 | PARP1 (0.59) | CREBBPBRD4PARP1MAOBMAOA | |
| SCHEMBL13870348 | 0.78 | PARP1 (0.57) | CREBBPBRD4PARP1MAOBMAOA | |
| SCHEMBL29498308 | 0.76 | MAOB (0.49) | CREBBPPARP1MAOBMAOANPC1 | |
| SCHEMBL19674624 | 0.75 | MAOB (0.51) | CREBBPPARP1MAOBMAOANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | claimed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | claimed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | HAX1, VEGFA, HYOU1 | CREBBP 2000/4885BRD4 565/4885PARP1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.